To provide updated recommendations for the management of Behçet’s syndrome, emphasizing earlier biologic use and the importance of individualized treatment strategies.
Key Findings:
Earlier use of biologic DMARDs is recommended for patients with eye, vascular, and nervous system involvement.
Colchicine remains the first-line treatment for mucocutaneous involvement.
For Behçet’s uveitis, immunosuppressive treatment is necessary for all patients.
High-dose glucocorticoids plus infliximab are recommended for arterial involvement.
Prompt treatment with glucocorticoids and immunosuppressives is emphasized for venous thrombosis.
Interpretation:
The updated recommendations reflect a shift towards earlier and more aggressive treatment strategies to prevent irreversible organ damage and enhance quality of life in Behçet’s syndrome patients.
Limitations:
Small size of randomized trials.
Heterogeneity in trial populations and outcome measures.
Reliance on observational data in several treatment domains.
Evidence gaps in treatment sequencing and management of refractory disease, particularly in the context of biologic therapies.
Conclusion:
The updated guidelines aim to enhance patient outcomes through timely intervention and a multidisciplinary approach that includes patient education and shared decision-making.
A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.
